Robert M. Nalbandian, M.D.; Raymond Henry, Ph.D.; Bruce Nichols, B.A.; Dale L. Kessler, M.D.; Frank R. Camp Jr.; Keats K. Vining Jr., M.D., (Associate)
This content is PDF only. Please click on the PDF icon to access.
We show that the molecular basis for the use of intravenous urea in the treatment of sickle cell crisis is supported by molecular pathology and in vitro experiments. We have been able to inhibit and to reverse sickling in both heterozygous and homozygous S intact erythrocytes without hemolysis by using urea in an osmotically balanced invert sugar solution. Also, concentrated hemolysates of both heterozygous and homozygous hemoglobin S have been prevented from gelling at 37 C with the use of urea, indicating inhibition of sickling. The molecular basis for the effectiveness of urea in blocking and reversing sickling is implicit
Nalbandian RM, Henry R, Nichols B, Kessler DL, Camp FR, Vining KK. The Molecular Basis for the Treatment of Sickle Cell Crisis by Intravenous Urea.. Ann Intern Med. ;72:795. doi: 10.7326/0003-4819-72-5-795_2
Download citation file:
Published: Ann Intern Med. 1970;72(5):795.
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use